Madrigal Pharmaceuticals acquires Pfizer

Madrigal Pharmaceuticals agreed to acquire Pfizer. Reported deal value: Undisclosed. Status: Announced. Sector: Pharmaceuticals. Target headquarters context: New York City, New York, United States.

This page summarizes publicly available information about the transaction as of 2026-01-13. Figures and status may change as filings and press coverage update.

Share on Facebook The commercial performance of Rezdiffra provides clear validation for Madrigal Pharmaceuticals ’ goalsCredit: [Piotr Swat]/Shutterstock.com Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer – ervogastat and two preclinical assets – as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis treatment space through leveraging early commercial success